Streetbeat News

Revenues

RTO

Levi & Korsinsky has initiated an investigation into Rentokil Initial plc (NYSE:RTO) for potential violations of federal securities laws. The investigation follows Rentokil's disclosure of a decline in expected full-year adjusted pretax profit due to weaker sales in North America.

Portfolio Pulse from

November 06, 2024 | 12:45 pm

VERX

Vertex, Inc. (NASDAQ: VERX) released its financial results for the third quarter of 2024, highlighting its performance as a global provider of indirect tax solutions.

Portfolio Pulse from

November 06, 2024 | 12:30 pm

RPRX

Royalty Pharma plc (Nasdaq: RPRX) reported its financial results for the third quarter of 2024 and increased its full-year guidance for Portfolio Receipts.

Portfolio Pulse from

November 06, 2024 | 12:30 pm

FLO

Flowers Foods is expected to report its Q3 earnings, which are anticipated to show gains from its portfolio strategy and cost-saving efforts despite a challenging consumer environment.

Portfolio Pulse from

November 06, 2024 | 12:30 pm

HLNE

Hamilton Lane Incorporated reported a 10% year-over-year growth in both management & advisory fees and assets under management for the second quarter of fiscal 2025.

Portfolio Pulse from

November 06, 2024 | 12:15 pm

AWSL

Atlantic Power & Infrastructure Corp.'s product, Flexi®-Pave, has been successful in urban landscaping in Las Vegas, leading to more planned projects.

Portfolio Pulse from

November 06, 2024 | 12:15 pm

MHH

Mastech Digital, Inc. (NYSE AMERICAN: MHH) reported strong financial results for Q3 2024, with an 8% year-over-year revenue growth and a 5% sequential growth. The company achieved record gross margins of 28.5% and significant increases in both GAAP and non-GAAP earnings per share.

Portfolio Pulse from

November 06, 2024 | 12:15 pm

ACB

Aurora Cannabis reported strong fiscal 2025 Q2 results with a record adjusted EBITDA of $10.1 million, a 210% YoY increase. Net revenue rose 29% YoY to $81.1 million, driven by 41% growth in global medical cannabis. The company maintains a strong balance sheet with $152 million in cash and no debt.

Portfolio Pulse from

November 06, 2024 | 12:15 pm

IMCR

Immunocore reported strong third quarter financial results with a 28% increase in net revenues for KIMMTRAK and a significant rise in EPS. The company is advancing its Phase 3 trials in melanoma and presented promising Phase 1 data in ovarian cancer.

Portfolio Pulse from

November 06, 2024 | 12:15 pm

TEVA

Teva Pharmaceuticals reported strong financial results for Q3 2024, driven by its generics and innovative portfolio. The company has raised its financial outlook for 2024, including revenues, adjusted EBITDA, and non-GAAP EPS.

Portfolio Pulse from

November 06, 2024 | 12:15 pm